Company / Revenue
Adaptimmune Therapeutics PLC Revenue History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$178.0M
FY2024
5-year range
$4.0M / $178.0M
FY2020-FY2024
Trend
+195.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has increased for 5 consecutive years, from $1M in FY2019 to $178M in FY2024.
Based on SEC 10-K filings.
$178M in FY2024 with a 5-year CAGR of +175.5%.
Improved from $27M to $178M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- +207.1%
- 5-Year CAGR
- +175.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- Adaptimmune Therapeutics PLC's revenue has grown for 5 consecutive years.
- 5-year CAGR of +175.5%, indicating consistent growth.
- In FY2024, revenue increased 195.3% year-over-year.
- Lowest revenue in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $178.0M | +195.3% |
| FY2023 | $60.3M | +122.0% |
| FY2022 | $27.1M | +341.5% |
| FY2021 | $6.1M | +55.4% |
| FY2020 | $4.0M | +252.8% |
| FY2019 | $1.1M | -98.1% |
| FY2018 | $59.5M | +57.3% |
| FY2017 | $37.8M | +166.5% |
| FY2016 | $14.2M | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026